CBSA adds four new board of directors members
Monday October 28, 2019 0 comments
DENVER -- Colorado BioScience Association (CBSA) announced the appointment of four new members to the CBSA board of directors.
They are: Elyse Blazevich, Securisyn Medical co-founder, chief operating officer and chief financial officer; April Giles, Fitzsimons Innovation Community VP of business development; Joseph Guiles, Agilent Technologies, Inc. head of development; and Andrew Sklawer, Brickell Bio co-founder and chief operating officer.
All four will serve three-year terms.
Selected for their experience leading high-growth organizations, developing partnerships and bringing life-saving products to market, the new board members are respected leaders in Colorado’s life sciences community.
Blazevich creates and executes strategies for Securisyn, which is dedicated to making airway management safer and focuses on eliminating unplanned extubation deaths.
Giles leads growth and partnership development for the Fitzsimons innovation community, an entrepreneurial environment that offers specialized space and services for more than 70 companies and organizations.
Guiles leads technical development teams at Agilent’s facilities in Boulder and Frederick, which specialize in supplying nucleic acid-based therapeutics to pharmaceutical and biotech company’s worldwide. Agilent’s corporate focus is to provide life sciences, diagnostics and applied chemical markets with instruments, services, consumables, applications and expertise.
Sklawer leads operations for Brickell Bio, a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for treatment of skin diseases.
“Our newest board members represent companies and organizations at all stages of innovation,” said Jennifer Jones Paton, CBSA president and CEO.
“They understand the support and leadership our life sciences ecosystem needs for success. We’re pleased to welcome leaders from Securisyn Medical, Fitzsimons Innovation Community, Agilent Technologies and Brickell Bio to the Colorado BioScience Association board of directors.”
The 29-person CBSA board of directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare, and research organizations.
Board members commit to work in partnership with CBSA staff to support the growth of Colorado’s more than 720 life sciences companies and organizations.